93 related articles for article (PubMed ID: 2168920)
1. Treatment with monoclonal anti-CD3 antibody protects against lethal Sendai virus infection by induction of natural killer cells.
Kast WM; Bluestone JA; Heemskerk MH; Spaargaren J; Voordouw AC; Ellenhorn JD; Melief CJ
J Immunol; 1990 Oct; 145(7):2254-9. PubMed ID: 2168920
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
Anderson PM; Blazar BR; Bach FH; Ochoa AC
J Immunol; 1989 Feb; 142(4):1383-94. PubMed ID: 2521662
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.
Ellenhorn JD; Schreiber H; Bluestone JA
J Immunol; 1990 Apr; 144(7):2840-6. PubMed ID: 1969454
[TBL] [Abstract][Full Text] [Related]
4. Induction and blocking of cytolysis in CD2+, CD3- NK and CD2+, CD3+ cytotoxic T lymphocytes via CD2 50 KD sheep erythrocyte receptor.
Bolhuis RL; Roozemond RC; van de Griend RJ
J Immunol; 1986 Jun; 136(11):3939-44. PubMed ID: 3084649
[TBL] [Abstract][Full Text] [Related]
5. Lectin-dependent and anti-CD3 induced cytotoxicity are preferentially mediated by peripheral blood cytotoxic T lymphocytes expressing Leu-7 antigen.
Phillips JH; Lanier LL
J Immunol; 1986 Mar; 136(5):1579-85. PubMed ID: 2419407
[TBL] [Abstract][Full Text] [Related]
6. Selective induction of autocytotoxic activity through the CD3 molecule.
Bensussan A; Leca G; Corvaïa N; Boumsell L
Eur J Immunol; 1990 Dec; 20(12):2615-9. PubMed ID: 2148523
[TBL] [Abstract][Full Text] [Related]
7. In vivo antitumor activity of anti-CD3-induced activated killer cells.
Yun YS; Hargrove ME; Ting CC
Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
[TBL] [Abstract][Full Text] [Related]
8. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
9. Effect of rabbit anti-asialo GM1 treatment in vivo or with anti-asialo GM1 plus complement in vitro on cytotoxic T cell activities.
Stitz L; Baenziger J; Pircher H; Hengartner H; Zinkernagel RM
J Immunol; 1986 Jun; 136(12):4674-80. PubMed ID: 3486908
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
[TBL] [Abstract][Full Text] [Related]
11. Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1.
van de Griend RJ; Tax WJ; van Krimpen BA; Vreugdenhil RJ; Ronteltap CP; Bolhuis RL
J Immunol; 1987 Mar; 138(5):1627-33. PubMed ID: 2949018
[TBL] [Abstract][Full Text] [Related]
12. Functional analysis of T lymphocyte subsets in antiviral host defense.
Leist TP; Cobbold SP; Waldmann H; Aguet M; Zinkernagel RM
J Immunol; 1987 Apr; 138(7):2278-81. PubMed ID: 2435794
[TBL] [Abstract][Full Text] [Related]
13. Activation of human cytolytic cells through CD2/T11. Comparison of the requirements for the induction and direction of lysis of tumor targets by T cells and NK cells.
Scott CF; Bolender S; McIntyre GD; Holldack J; Lambert JM; Venkatesh YP; Morimoto C; Ritz J; Schlossman SF
J Immunol; 1989 Jun; 142(11):4105-12. PubMed ID: 2565930
[TBL] [Abstract][Full Text] [Related]
14. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
15. Generation of large granular T lymphocytes in vivo during viral infection.
Biron CA; Natuk RJ; Welsh RM
J Immunol; 1986 Mar; 136(6):2280-6. PubMed ID: 3485144
[TBL] [Abstract][Full Text] [Related]
16. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
[TBL] [Abstract][Full Text] [Related]
17. Induction of CD8+ T cell responses to dominant and subdominant epitopes and protective immunity to Sendai virus infection by DNA vaccination.
Chen Y; Webster RG; Woodland DL
J Immunol; 1998 Mar; 160(5):2425-32. PubMed ID: 9498786
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of skin xenograft rejection by depleting T-cell receptor alpha beta-bearing cells without T-cell receptor gamma delta-bearing cells or natural killer cells by monoclonal antibody.
Nishimura Y; Eto M; Maeda T; Hiromatsu K; Kobayashi N; Nomoto K; Kong YY; Nomoto K
Immunology; 1994 Oct; 83(2):196-204. PubMed ID: 7835935
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T lymphocyte unresponsiveness induced by prolonged treatment with immobilized anti-CD3 antibody. Association of impairment of cytolytic activity with temporary depletion of intracellular protein kinase C.
Sano S; Kiyotaki C; Tatsumi Y; Fujiwara H; Hamaoka T
J Immunol; 1989 Nov; 143(9):2797-805. PubMed ID: 2530277
[TBL] [Abstract][Full Text] [Related]
20. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
